secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001140361-23-057644
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis appoints Michael Yang to Board of Directors, expanding board to 10
------------------------------------------------------------------------

- Michael Yang appointed to Ionis board effective December 14, 2023.
- Yang most recently served as CEO of ViaCyte, acquired by Vertex in 2022.
- Former EVP & Chief Commercial Officer at Acadia Pharmaceuticals (2017-2021).
- Yang previously President of Janssen Biotech, generating over $8B in annual revenues.
- Will receive standard non-employee director cash and equity compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123057644/0001140361-23-057644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123057644/ef20016672_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-057644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer